It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Underwriters for Intarcia Therapeutics Inc. on Friday set the terms of the company's pending initial public offering at five million shares with an estimated price range of $12 to $14 a share. Diabetes ‘Unicorn’ Raises Final VC Round Before IPO Intarcia Therapeutics, Inc. 15 Sep 2016. Diabetes ‘Unicorn’ Raises Final VC Round Before IPO. Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation . In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. Sector. In February 2018, Intarcia CEO Kurt Graves told the Business Journal that the company hoped to resubmit its approval application around mid-year. But as of late September — the one-year anniversary of the rejection — a company spokesperson said Intarcia still had not submitted that application. 10Q, S-1 and other registration statement filings. Sector. Intarcia Therapeutics, Inc. is a biopharmaceutical company dedicated to improving real-world adherence and real-world outcomes in some of our nation’s most costly and devastating chronic diseases by leveraging the convergence of medicines and novel delivery technologies. Negative Outlook. intarcia.com | BioTech | Founded: 1997 | Funding to Date: $961,464,514. Its flagship product, Medici Drug Delivery System, has the potential to transform the prevention and management of serious chronic diseases. Year Funded. In September 2017 the FDA rejected ITCA 650 due to concerns regarding manufacturing issues. Cons. Intarcia Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops and commercializes therapies to enhance treatment outcomes. Intarcia Therapeutics serves patients throughout the United States. NO. OF EMPLOYEES Intarcia Therapeutics has filed for FDA approval of its osmotic mini-pump Type 2 diabetes treatment. Intarcia Therapeutics is a biopharmaceutical company developing therapies for chronic diseases. Intarcia Therapeutics Closes $215M First Close of Equity Financing Funding Health. intarcia.com | BioTech | Funding to Date: $961,464,514. UNLOCKING LIFE’S POSSIBLITIES: Intarcia Therapeutics. Sign up to get notified as soon as new Intarcia Therapeutics jobs are posted. Intarcia develops therapies for diseases that require long-term chronic treatment such as Type 2 diabetes. Private Healthcare, Therapeutics-Biologics. Cullinan Management (CGEM) intends to raise $150 million from the sale of its common stock in an At a time when biotechnology companies in even earlier stages of clinical development are choosing to IPO in record numbers, it is interesting that Intarcia has The well-funded company has said publicly it is unlikely to seek an initial public offering prior to commercialization of its lead product for fear of leaving value on the table. Intarcia Therapeutics scraps IPO. It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004. The Baillie Gifford portfolio alone contains Ginkgo, Flatiron and Intarcia along with therapeutics companies CureVac, Denali Therapeutics and UNITY Biotechnology. Beyond bringing Intarcia yet more instant cash, the $225m royalty financing the private group pulled off this week looks like an unusual way of putting a real valuation both on itself and its key asset, the exenatide-secreting implant ITCA 650. Dubbed a biotech "unicorn" due to its lofty valuation, Intarcia has a strong cash position, raising over $600 million through September in a private equity financing. The initial public offering of Intarcia Therapeutics Inc. was pulled due to market conditions, an underwriter said on Wednesday. Doesn't Recommend. Aims Evaluate the efficacy and tolerability of ITCA 650 in subjects with type 2 diabetes treated for up to 48 weeks. Pros. Boston-based Intar­cia Ther­a­peu­tics be­came the lat­est ca­su­al­ty of the FDA’s man­u­fac­tur­ing stan­dards. Phone Number 617-936-2500. Hands on experience in SEC and IPO related filings including Form 10K. See the full leadership team at Craft. Intarcia Therapeutics Inc Intarcia Therapeutics, Inc. operates as a biopharmaceutical company. Intarcia Therapeutics has a great product that will help many people " (in 6 reviews) " good pay, nice team environment " (in 5 reviews) Cons. " The company offers research and development, manufacturing, marketing and distribution services. Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware. Intarcia Therapeutics Stock. Overall, it's a good company. Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. Intarcia Therapeutics, a Boston-based company looking to revolutionize treatment for Type … Pros. " It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides. Intarcia is a biotech company dedicated to redesigning the … $75,000,000 Debt financing MassDevice. They're struggling getting the drug approved by the FDA. The company has not officially endorsed a plan to participate in an IPO. Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis. Before joining the Company, Ray served as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary of Intarcia Therapeutics, Inc. from September 2013 through April 2020. Less than two months before the FDA rejected Intarcia Therapeutics ’ potential blockbuster treatment for type 2 diabetes last year, inspectors at the agency faulted the Boston-based company for a litany of manufacturing issues and warned about potential drug contamination, a newly-obtained document shows. Intarcia is committed to unleashing new ways to treat and prevent chronic disease. We are developing a pipeline of innovative therapies that merge medicine with technology to help transform therapeutic categories in chronic diseases. Interested in learning more about how Intarcia is carrying out its vision? References in this prospectus to "we," "us" and "our" refer to Intarcia Therapeutics, Inc. Our Company . Their lead drug candidate, ITCA 650, is a treatment for Type 2 diabetes that is currently in Phase 3 clinical trials. Other executives include Bryan Roberts, Director; Thomas Alessi, Vice President, Development and Manufacturing and 9 others. I worked at Intarcia Therapeutics full-time for more than 3 years. Intarcia is a biotech company focused on developing innovative therapies utilizing a proprietary delivery system – medicines that have the potential to … Intarcia Therapeutics, Inc. 15 Sep 2016. 2003. Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. BOSTON, Oct. 8, 2019 /PRNewswire/ -- Intarcia Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its new drug application (NDA) for ITCA 650 (exenatide implant), for the treatment of type 2 diabetes mellitus.... Oct 8, 2019. www.prnewswire.com. Intarcia Therapeutics IPO. Investment Status. Everything.”. The deal was initially expected to price on Tuesday. The biopharmaceutical company had filed for an offering of 5 million shares at an estimated price of $12 to $14 each. On Feb. 7, Intarcia filed an IPO to sell up to $86.25 million in … Intarcia Therapeutics was founded in 1997 by David Franklin, James M. Ahlers, and Thomas Alessi. Wish they had more room for growth, but at the moment they do not. Once they go commercial they my open up more jobs. This week the U.S. Food and Drug Administration (FDA) issued its second Complete Response Letter for the device. Boston-based Intarcia continues to run into a regulatory roadblock concerning its implanted diabetic pump ITCA 650. Tags: Phase 3 Financing - Company secures $225M financing in exchange for 1.5% of future global net sales of ITCA 650, a novel once or twice yearly and injection-free GLP-1 therapy currently in phase 3 clinical development to treat type 2 diabetes. The submission triggered a $100 million payment, giving Intarcia some of … FinSMEs. The toxic environment from working with the swing shift and the politics. ITCA 650 Company sites Boston and Hayward have completely different cultures " (in 7 reviews) " No one there knows what they are doing " (in 6 reviews) More Pros and Cons. Intarcia is much further along than that—ITCA 650 is in the midst of an extensive Phase 3 program in type 2 diabetes. investors to fully recoup their investment, and in the meantime, Intarcia undertakes no immediate debt or payment obligations and no immediate dilution. Intarcia Therapeutics is a biopharmaceutical company that provides a variety of services in addition to its proprietary products. After addressing those concerns, Intarcia resubmitted its … Less than two months before the FDA rejected Intarcia Therapeutics’ potential blockbuster treatment for type 2 diabetes last year, inspectors at … Intarcia Therapeutics's Chairman, President and CEO is Kurt Graves. About Intarcia Therapeutics, Inc.Intarcia Therapeutics, Inc. is an independent, privately held, biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. “Everything you do as a company—everything you say, how you express yourself—counts. We would like to show you a description here but the site won’t allow us. The pros to this place was working with a great manufacturing team on Dayshift. Baillie Gifford is not the only fund coming into life sciences and healthcare investments with big dollars and long-term views. Senior Buyer Intarcia Therapeutics (Current Employee) - Hayward, CA - February 3, 2020. The Company develops and commercializes therapies to enhance treatment outcomes. Disapproves of CEO. Intarcia is developing innovative therapies, merging medicine and technology. There are currently no open jobs at Intarcia Therapeutics listed on Glassdoor. Private. Intarcia Therapeutics, Inc. is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. The Intarcia DUROS drug delivery platform stabilizes and delivers therapeutic proteins and peptides. Intarcia Therapeutics Inc. is withdrawing its initial public offering due to poor market conditions, the company announced late … ZELTIQ is focused on developing products utilizing its proprietary controlled-cooling technology.